ECE2014 Poster Presentations Endocrine tumours and neoplasia (99 abstracts)
Efficacy of lanreotide autogel in men1-related gastrinomas: a case series
Donato Iacovazzo 1 , Francesca Lugli 1 , Antonio Bianchi 1 , Ettore Capoluongo 2 , Emanuela Lucci-Cordisco 3 , Roberto Persiani 4 , Giovanni Battista Doglietto 5 , Alfredo Pontecorvi 1 , Guido Rindi 6 & Laura De Marinis 1
1Endocrinology - Universita’ Cattolica del Sacro Cuore, Rome, Italy; 2Biochemistry and Clinical Biochemistry - Universita’ Cattolica del Sacro Cuore, Rome, Italy; 3Medical Genetics - Universita’ Cattolica del Sacro Cuore, Rome, Italy; 4General Surgery - Universita’ Cattolica del Sacro Cuore, Rome, Italy; 5Digestive Surgery - Universita’ Cattolica del Sacro Cuore, Rome, Italy; 6Anatomic Pathology - Universita’ Cattolica del Sacro Cuore, Rome, Italy.
GEP NETs, especially gastrinomas, occur in 40–70% of MEN1 patients and represent the main cause of death in these patients.
We aim to investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.
We report a monocentric series of seven MEN1 patients (three M, and four F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at diagnosis, 3 months after starting lanreotide and then every 6 months. Five of the seven patients underwent surgery, at least 3 months after starting lanreotide treatment, while two patients refused surgical treatment.
Mean plasma gastrin levels at diagnosis were 5562 pg/ml (1300–17 178 pg/ml; n.v. 30–115) and fell, after 3 months of treatment, to 117.1 pg/ml (53–241 pg/ml; mean reduction 78.9%). Five patients underwent surgery and three of these had persistent hypergastrinemia. In these patients, the treatment with lanreotide was resumed with normalization of gastrin plasma levels and disease stabilization. Two patients refused surgery: during follow-up gastrin levels remained controlled with no evidence of disease progression.
Lanreotide ATG proved efficacy in the biochemical control of hypergastrinemia with normalization of plasma gastrin levels in 70% of patients and a mean reduction of 78.9% after the first 3 months of treatment. Moreover, lanreotide demonstrated efficacy in the long-term control of disease and allowed tumor stabilization in all patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more